Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An autosomal recessive syndrome characterized by joint contractures, skeletal abnormalities, anterior segment anomalies of the eye and early lethality.
Features include always present findings: Cloudy or opaque cornea (corneal opacity), Polyhydramnios, Gastrojejunal tube feeding in infancy, and Proximal radio-ulnar synostosis and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Bones and joints | 2 | Mild bone density loss (osteopenia), Recurrent fractures |
B3GALT6 encodes beta-1,3-galactosyltransferase 6 (329 aa). Beta-1,3-galactosyltransferase that transfers galactose from UDP-galactose to substrates with a terminal beta-linked galactose residue. Highest expression in Cells Cultured fibroblasts (29.9 TPM) and Uterus (23.1 TPM).
Al-Gazali syndrome is associated with mutations in the B3GALT6 gene on chromosome 1.
The B3GALT6 protein participates in B3GALT6 R197Afs*81 and Defective B3GALT6 causes EDSP2 and SEMDJL1 pathways.
B3GALT6 is classified as a druggable target (Enzyme category) with score 0.0.
Al-Gazali syndrome is included in newborn screening programs (Medium/Short-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency) in 24 states.
Genetic testing for B3GALT6 is available. Testing is considered confirmatory for diagnosis.
Phenotype severity distribution: 16 always present features.
No clinical trials have been registered for Al-Gazali syndrome.
2 publications have been identified in PubMed for Al-Gazali syndrome. Research spans Review / Meta-Analysis (50%) and Basic Science / Preclinical (50%).
Maheshati A (2025). [PMID: 40371684](https://pubmed.ncbi.nlm.nih.gov/40371684/). *Orthop Surg*. [Review / Meta-Analysis]
Diana RM (2025). [PMID: 40857410](https://pubmed.ncbi.nlm.nih.gov/40857410/). *JCI Insight*. [Basic Science / Preclinical]
Data assembled from 7 of 12 sources · Last updated Sep 20, 2026, 8:41 AM UTC
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Al-Gazali syndrome
Eyes
1 |
Cloudy or opaque cornea (corneal opacity) |
Digestive system | 1 | Gastrojejunal tube feeding in infancy |
Growth and development | 1 | Failure to thrive |
Muscles | 1 | Wrist flexion contracture |
Lungs and breathing | 1 | Recurrent pneumonia |
Arms and legs | 1 | Broad distal phalanx of finger |
AI-curated news mentioning Al-Gazali syndrome
Updated Feb 19, 2026
Key neurology trials are set to report data in early 2026, including the ADEPT-2 study on xanomeline/trospium for Alzheimer's psychosis and the ELEVATE-PD trial on IPX203 for Parkinson's. These studies may introduce new therapies and impact treatment strategies for Alzheimer's and Parkinson's disease.